A multicenter study on early prediction of antipsychotic response in patients with schizophrenia

A multicenter study on early prediction of antipsychotic response in patients with schizophrenia - A multicenter study on early prediction of antipsychotic response in patients with schizophrenia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001862

Enrollment

500

Registered

2009-06-01

Start date

2009-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia

Interventions

olanzapine/risperidone risperidone/olanzapine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: schizophrenia, schizophreniform disorder, schizoaffective disorder (DSM-IV: 295.xx)

Exclusion criteria

Exclusion criteria: 1) severe liver, renal, respiratory, or cardiac dysfunction 2) diabetes melitus or its history 3) women during pregnancy or nurse, women who want to get pregnant

Design outcomes

Primary

Measure	Time frame
The rate of remission at 4 weeks after the beginning of antipsychotics	—

Secondary

Measure	Time frame
the Positive and Negative Syndrome Scale (PANSS) ,Clinical Global Impression Change rating scale,Global Assessment of Functioning,the Drug-induced Extrapyramidal Symptom Scale ,blood sugar, total cholesterol, triglyceride	—

Countries

Japan

Contacts

Public ContactKotaro Hatta

Juntendo University School of Medicine Department of Psychiatry

khatta@juntendo.ac.jp03-5802-1071

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026